Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
(Thomson Reuters ONE) -
AstraZeneca speeds R&D decision making with cutting-edge life sciences
technology
PHILADELPHIA, PA, April 24, 2012 - The Intellectual Property & Science division
of Thomson Reuters today announced its commitment to support R&D pharmaceutical
leaders with a new oncology application for mobile tablet devices, already in
use by AstraZeneca executives. The rich visualization dashboard leverages
content from Thomson Reuters Cortellis, the company's flagship life sciences
platform, and provides real-time data for clinical oncology drug research and
development activities.
"Oncology is critical for pharma, as is evidenced by the World Health
Organization's projection that an estimated 13.1 million people will die from
cancer in 2030, up from the 7.6 million who died in 2008," said Wendy Hamilton,
senior vice president at Thomson Reuters. "The ability of drug companies to
quickly find the most relevant research data and clinical information for their
oncology studies, in meetings, on the move or at the bench, will allow them to
make faster business decisions and focus on areas where there is unmet need."
The solution provides a series of oncology-based clinical dashboards that
provide competitive information that quickly answers common questions in drug
development. It is platform independent and accessible via the Internet. Mobile
tablet-based devices are the primary method used for accessing the solution.
Users see at-a-glance, side-by-side comparisons of adverse events for drugs
already on the market or in clinical trials. They get a deeper understanding of
the drugs and how they are being targeted for diseases by segment. The
comparisons visualize the level of current research and development activity
around an indication, whether by company or mechanism of action, together with
information on ongoing clinical trials.
The new applications represent the initial output in an ongoing partnership
between Thomson Reuters and AstraZeneca, with other applications due to be
released this year. The Thomson Reuters Life Sciences Professional Services team
is working on similar innovative projects for other customers too.
Launched in late 2011, Cortellis is the most powerful tool of its kind for
biopharmaceutical competitive intelligence, drug pipeline, and drug research and
development. For more information on the oncology decision support dashboards
and Cortellis, go to http://cortellis.thomsonreuters.com/.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACTS
Laura Gaze
Thomson Reuters
+1 203 868 3340
laura.gaze(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1605476]
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2012 - 15:08 Uhr
Sprache: Deutsch
News-ID 138616
Anzahl Zeichen: 4153
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
